Drug Profile
Nafagrel
Alternative Names: DP 1904; SR 96325Latest Information Update: 19 Dec 2000
Price :
$50
*
At a glance
- Originator Daiichi Pharmaceutical
- Developer Daiichi Pharmaceutical; Sanofi-Synthelabo
- Class Anti-ischaemics; Antiplatelets; Imidazoles; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Thromboxane A2 synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Asthma; Diabetic angiopathies; Heart failure; Raynaud's disease
Most Recent Events
- 19 Dec 2000 Discontinued-Clinical for Raynaud's disease in Japan (PO)
- 19 Dec 2000 Discontinued-Unspecified phase in Diabetic angiopathies in Japan (Unknown route)
- 19 Dec 2000 Discontinued-Unspecified phase in Heart failure in Europe (Unknown route)